Literature DB >> 1920806

[Sevoflurane with continuous epidural anesthesia for removal of pheochromocytoma].

S Tanaka1, M Miyabe, I Ohyama, S Seki, T Tsukamoto, A Namiki.   

Abstract

A 66-year-old female was scheduled for right adrenalectomy because of a pheochromocytoma. Preoperative blood pressure was well controlled with an alpha.beta blocker, amosulalol hydrochloride 40 mg per day po for 2 weeks. The patient received midazolam 2.5 mg im and scopolamine 0.4 mg im 60 minutes before induction. Anesthesia was induced with midazolam 5 mg iv, fentanyl 0.1 mg iv and vecuronium 12 mg iv, and maintained with continuous epidural infusion of 1.5% lidocaine, and inhalation of 66% nitrous oxide in oxygen and sevoflurane (0.5-3%). Blood pressure was controlled with nicardipine (1-6 micrograms.kg-1.min-1) before removal of the pheochromocytoma. After removal of the tumor blood pressure was maintained with intravenous infusion of lactated Ringer's solution, dopamine (3-8 micrograms.kg-1.min-1), dobutamine (3-8 micrograms.kg-1.min-1) and norepinephrine (0.1-0.2 micrograms.kg-1.min-1). A combination of continuous epidural block and sevoflurane anesthesia was very useful for removal of the pheochromocytoma. Swan-Ganz catheter monitoring was also very useful before and during operation to determine the optimal doses of nicardipine, catecholamine and the volume of transfusion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1920806

Source DB:  PubMed          Journal:  Masui        ISSN: 0021-4892


  2 in total

Review 1.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

2.  Role of dexmedetomidine and sevoflurane in the intraoperative management of patient undergoing resection of phaeochromocytoma.

Authors:  Monica Khetarpal; Monu Yadav; Dilip Kulkarni; R Gopinath
Journal:  Indian J Anaesth       Date:  2014-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.